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Introduction
The following questions are put together to solicit opinion from expert virologists. Please 
indicate your answers quantitatively and provide comments which may give rational for 
your answers. The aim is to determine areas of agreement and uncertainty and to assist 
the parametrisation of mathematical models.
 
 
Definitions
The focus here is specifically on PrEP being a daily oral dose of TDF or TDF/FTC, and ART 
being TDF-based. Please indicate if you use data that do not correspond to these definitions. 
 
 
Instructions
For each question there is a line with a scale and we ask for an indication of where on 
that line the true value lies (location and uncertainty). In the example below, a question 
is asked about the rate ratio of an event and a scale is provided (note, a logarithmic 
scale); the respondent has indicated (in red) that the rate is usually less than 1.0, but 
not usually more than 0.3 and with a typical value of approximately 0.5
 
 
 
 
Please provide comments which may give rational for your answers (optional)
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1. Rate of resistance development for HIV+ PrEP users. 
 
 
a) What is the average time it takes for resistance to develop (to any detectable level) in 
users who acquire HIV and subsequently use PrEP with perfect compliance?
 
 
 
 
b) What is the average time it takes for resistance to develop (to any detectable level) 
in users who acquire HIV and subsequently use PrEP with intermittent compliance 
(missing doses every other day). 
 
 
 
 
 
 
c) What is the average time it takes for resistance to develop (to any detectable level) in 
users who acquire HIV and subsequently use PrEP with low compliance (taking only 1 
dose per week). 
 
 
 
 
NB. These guidelines are not drawn to scale.
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2. Transmission from an individual with acquired drug-resistant HIV
 
a) For an individual that had acquired drug-resistance whilst on PrEP but who now has 
not used PrEP for one week, what is the relative chance of transmitting a resistant virus 
compared to a wild-type virus (given that infection has occured).
 
i. … to someone who is not on PrEP
 
 
 
 
 
ii. … to someone who is currently taking PrEP (and in good compliance)
 
 
 
 
 
b) For an individual that acquire drug-resistance whilst on PrEP but who now has not 
been using PrEP for one year, what is the relative chance of transmitting a resistant 
virus compared to a wild-type virus (given that infection has occured) .
Note: This could change after one year due to reversion
 
i. … to someone who is not on PrEP
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ii.  …  to someone who is currently taking PrEP (and in good compliance)
 
 
 
c) What is the level of protection of PrEP against drug-resistant HIV (Assumed level of 
protection against wild type HIV is provided.)
 
 
 
 
 
3. Reversion of Drug Resistance
 
a) For an individual that had acquired drug-resistance whilst on PrEP but who now 
has not used PrEP what is the proportion of resistant virus compared to a total viral 
population over time after discontinue PrEP use.
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b) For an individual that has transmitted drug-resistance and never used PrEP what 
is the proportion of resistant virus compared to a total viral population over time after 
transmission. (Note: Insert graph)
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4. Characteristic of Transmitted Drug Resistance
 
If drug-resistant HIV is transmitted, what will be relative chance of transmitting to 
someone else (compared to if the infection has been a wild-type virus: lower/same/
higher), and what is the probability that the transmitted virus is resistant virus:
 
 
a) One week after infection;
 
Relative chance of transmission (of any type of virus) compared if infected with wild-
type:
 
 
 
Probability that the transmitted virus is resistant virus (if transmission occurs):
 
 
 
 
 
b) One year  after infection;
 
Relative chance of transmission (of any type of virus) compared if infected with wild-
type:
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Probability that the transmitted virus is resistant virus (if transmission occurs): 
 
 
 
c) Five years after infection. 
 
Relative chance of transmission (of any type of virus) compared if infected with wild-
type:
 
 
 
Probability that the transmitted virus is resistant virus (if transmission occurs):
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5) Survival and disease progression when infected with drug-resistant HIV
 
 
a) In absence of ART what is the time from Infection to AIDS  (shorter/same/longer cf 
wild-type) if infected with:
 
PrEP-Acquired drug-resistance:
 
 
 
 
Transmitted drug-resistance:
 
 
NB. The guidelines are not drawn to scale.
 
 
b) Probability of suppression on first-line ART in the first year. (lower/same/higher cf 
wild-type) if infected with:
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Acquired drug-resistance:
 
 
 
 
 
Transmitted drug-resistance:
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